Junshi Biosciences Gains Approval for New HCC Treatment

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an announcement.

Shanghai Junshi Biosciences Co., Ltd. announced the approval of its supplemental new drug application for toripalimab in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (HCC) in China. This approval, based on the successful HEPATORCH study, marks the 11th indication for toripalimab in China and highlights its efficacy in extending progression-free and overall survival rates for HCC patients. The approval strengthens Junshi Biosciences’ position in the oncology market and offers a promising treatment option for a significant health challenge in China, where liver cancer is prevalent.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a Chinese pharmaceutical company specializing in the development and production of innovative drugs, particularly focusing on monoclonal antibodies. The company has a strong presence in the oncology sector, with its flagship product, toripalimab, being a leading anti-PD-1 monoclonal antibody in China.

YTD Price Performance: 31.61%

Average Trading Volume: 1,527,996

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$28.14B

For an in-depth examination of 1877 stock, go to TipRanks’ Stock Analysis page.